| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study
|
Cassier, P.A.
|
|
|
25 |
9 |
p. 1854-1860
|
artikel
|
| 2 |
Adverse events with everolimus in BOLERO-2
|
Neven, P.
|
|
|
25 |
9 |
p. 1861
|
artikel
|
| 3 |
‘An ounce of prevention is worth a pound of cure’: the case for and against GnRH-agonist for fertility preservation
|
Blumenfeld, Z.
|
|
|
25 |
9 |
p. 1719-1728
|
artikel
|
| 4 |
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
|
Aglietta, M.
|
|
|
25 |
9 |
p. 1750-1755
|
artikel
|
| 5 |
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma
|
Rini, B.
|
|
|
25 |
9 |
p. 1794-1799
|
artikel
|
| 6 |
A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study
|
Selle, F.
|
|
|
25 |
9 |
p. 1775-1782
|
artikel
|
| 7 |
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck †
|
Seiwert, T.Y.
|
|
|
25 |
9 |
p. 1813-1820
|
artikel
|
| 8 |
Birth weight and adult cancer incidence: large prospective study and meta-analysis
|
Yang, T.O.
|
|
|
25 |
9 |
p. 1836-1843
|
artikel
|
| 9 |
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
|
De Mattos-Arruda, L.
|
|
|
25 |
9 |
p. 1729-1735
|
artikel
|
| 10 |
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
|
Ciardiello, F.
|
|
|
25 |
9 |
p. 1756-1761
|
artikel
|
| 11 |
Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial
|
De Santis, M.
|
|
|
25 |
9 |
p. 1789-1794
|
artikel
|
| 12 |
Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)
|
Ciardiello, F.
|
|
|
25 |
9 |
p. 1673-1678
|
artikel
|
| 13 |
Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice
|
Booth, C.M.
|
|
|
25 |
9 |
p. 1783-1788
|
artikel
|
| 14 |
Editorial Board
|
|
|
|
25 |
9 |
p. ii-iii
|
artikel
|
| 15 |
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
|
Mittendorf, E.A.
|
|
|
25 |
9 |
p. 1735-1742
|
artikel
|
| 16 |
Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome)
|
Dummer, R.
|
|
|
25 |
9 |
p. 1807-1812
|
artikel
|
| 17 |
Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy
|
Wen, J.
|
|
|
25 |
9 |
p. 1769-1774
|
artikel
|
| 18 |
History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis
|
Chao, C.
|
|
|
25 |
9 |
p. 1821-1829
|
artikel
|
| 19 |
In reply to Gandaglia et al.
|
De Bari, B.
|
|
|
25 |
9 |
p. 1861-1862
|
artikel
|
| 20 |
In reply to the letter to the editor ‘in Reply to Gandaglia et al.’ by De Bari et al.
|
Gandaglia, G.
|
|
|
25 |
9 |
p. 1862-1863
|
artikel
|
| 21 |
Intensive care in patients with lung cancer: a multinational study
|
Soares, M.
|
|
|
25 |
9 |
p. 1829-1835
|
artikel
|
| 22 |
Letter to the editor on ‘Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small cell lung cancer’
|
Park, K.
|
|
|
25 |
9 |
p. 1866
|
artikel
|
| 23 |
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
|
Adenis, A.
|
|
|
25 |
9 |
p. 1762-1769
|
artikel
|
| 24 |
Miracles don't happen any more
|
Beyer, Jörg
|
|
|
25 |
9 |
p. 1679-1680
|
artikel
|
| 25 |
New agents for prostate cancer
|
Agarwal, N.
|
|
|
25 |
9 |
p. 1700-1709
|
artikel
|
| 26 |
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL
|
Murawski, N.
|
|
|
25 |
9 |
p. 1800-1806
|
artikel
|
| 27 |
Overall survival benefit from surgical resection in treatment of recurrent glioblastoma
|
Mann, B.S.
|
|
|
25 |
9 |
p. 1866-1867
|
artikel
|
| 28 |
Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer
|
Lueza, B.
|
|
|
25 |
9 |
p. 1865-1866
|
artikel
|
| 29 |
Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)
|
Vehreschild, J.J.
|
|
|
25 |
9 |
p. 1709-1718
|
artikel
|
| 30 |
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal
|
Valent, P.
|
|
|
25 |
9 |
p. 1691-1700
|
artikel
|
| 31 |
Reply to the letter to the editor ‘Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper’ by Valentini et al.
|
Popescu, R.
|
|
|
25 |
9 |
p. 1865
|
artikel
|
| 32 |
S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
|
Yoshida, M.
|
|
|
25 |
9 |
p. 1743-1749
|
artikel
|
| 33 |
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
|
Kerr, K.M.
|
|
|
25 |
9 |
p. 1681-1690
|
artikel
|
| 34 |
Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals of Oncology 25(1): 9–15, 2014)
|
Valentini, V.
|
|
|
25 |
9 |
p. 1863-1865
|
artikel
|
| 35 |
Table of Contents
|
|
|
|
25 |
9 |
p. iv-vi
|
artikel
|
| 36 |
Trends in mortality from major cancers in the Americas: 1980–2010
|
Chatenoud, L.
|
|
|
25 |
9 |
p. 1843-1853
|
artikel
|
Tijdschrift beschrijving